Partnership with RoosterBio to advance scalable & continuous exosomes manufacture
- Proof-of-concept of exosomes manufacturing in scale-X™ bioreactor to demonstrate advantages of intensified and integrated platforms
- RoosterBio to leverage scalable, continuous bioprocessing technologies to deliver regenerative therapies at reduced timelines and costs, improving access for patients
Belgium and United States – Univercells Technologies, a leading provider of novel biomanufacturing technologies for flexible and scalable viral production, announces today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and hMSC bioprocess systems. This partnership will optimize manufacturing of extracellular vesicles (EVs) using scalable and continuous bioprocessing technologies to propel the commercialization of regenerative therapies at affordable costs.
The goal is to deliver complete solutions for exosomes manufacture, leveraging Univercells Technologies’ intensified and integrated platforms and RoosterBio’s hMSC bioprocess and highly engineered media systems. As part of the partnership, RoosterBio will establish EV production process using their hMSCs from microcarriers in the scale-X™ hydro fixed-bed bioreactor which features 2.4 m² surface for cell growth. Following initial optimization to confirm cell growth, productivity, and product quality, Univercells Technologies and RoosterBio will collaborate in the development of a continuous process in perfusion mode. Through the use of intensified and integrated technologies, this joint effort will enable developers to accelerate timelines, reduce costs, and manufacture their regenerative therapies via a scalable, commercially viable platform.
”We are continuously seeking disruptive technologies to expand the impact of our innovative hMSC and EV products and bioprocess solutions”, stated Tim Kelly, CEO of RoosterBio. “Together, Univercells Technologies and RoosterBio will leverage our novel technologies and expertise to accelerate our customers’ journey from preclinical development to commercialization, reducing complexity and costs to make these life-saving therapies accessible for all patients.”
“Exosomes have emerged as a promising technology for advanced therapies such as viral vaccines and gene therapies. We are proud to partner with RoosterBio to demonstrate how purposefully designed technologies such as the scale-X bioreactor portfolio can enable the rapid delivery of reliable and affordable regenerative therapies,” says Mathias Garny, CEO of Univercells Technologies.
Both companies will look into extending this study among the scale-X carbo bioreactor (10 and 30 m² growth surface) with integrated in-line product concentration enabling continuous exosomes manufacturing.
About Univercells Technologies
Univercells Technologies is a global provider of innovative biomanufacturing technologies to achieve cost-effective viral production from R&D to commercial scales. The company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells Technologies is committed to helping customers increase performance with minimized footprint and costs today, while anticipating the needs of tomorrow.
Building upon years of expertise and capitalizing on technology vetted by world leaders, Univercells Technologies was incorporated in Belgium in 2020 following its carve-out from Univercells with the support of the Univercells Group and Gamma Biosciences.
LinkedIn: Univercells Technologies
About RoosterBio
RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and extracellular vesicle (EV) product and process development to fuel the rapid commercialization of scalable regenerative cures. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and EV production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type 2 Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under 1 year.
RoosterBio is driven by our client’s success and creating a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale.
LinkedIn: RoosterBio
